Abstract
Impairments in social cognition are now recognized as core illness features in psychotic and affective disorders. Despite the significant disability caused by social cognitive abnormalities, treatments for this symptom dimension are lacking. Here, we describe the evidence demonstrating abnormalities in social cognition in schizophrenia, major depressive disorder, and bipolar disorder, as well as the neurobiology of social cognition including the role of oxytocin. We then review clinical trials of oxytocin administration in psychotic and affective disorders and the impact of this agent on social cognition. To date, several studies have demonstrated that oxytocin may improve social cognition in schizophrenia; too few studies have been conducted in affective disorders to determine the effect of oxytocin on social cognition in these disorders. Future work is needed to clarify which aspects of social cognition may be improved with oxytocin treatment in psychotic and affective disorders. © 2014 Elsevier B.V. and ECNP.
| Original language | English |
|---|---|
| Pages (from-to) | 265-282 |
| Number of pages | 18 |
| Journal | Eur. Neuropsychopharmacol. |
| Volume | 25 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2015 |
Keywords
- Bipolar disorder
- Major depressive disorder
- Oxytocin
- Schizophrenia
- Social cognition
- Clinical Trials as Topic
- Cognition
- Humans
- Mood Disorders
- Psychotic Disorders
- Psychotropic Drugs
- Social Perception
- oxytocin
- psychotropic agent
- Article
- bipolar disorder
- clinical trial (topic)
- depression
- drug mechanism
- emotion
- human
- major depression
- mood disorder
- priority journal
- psychosis
- recognition
- schizophrenia
- social cognition
- theory of mind
- cognition
- drug effects
- perception
- psychology